Navigation Links
5-Year Follow-Up Outpatient of L4-L5 Fixation with Inspan Device for Degenerative Spinal Stenosis Demonstrates Improved Results
Date:2/11/2020

INSPAN LLC (a privately-owned company) is pleased to announce the successful results from a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous fixation for degenerative spinal stenosis using the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block design, the Inspan device fixates the spine to allow for immediate stability, distraction, decompression, and fusion. Based on biomechanical studies, the Inspan device may be the strongest interspinous fixation device on the market and thus is being used for spinal fusion replacing the traditional method that uses pedicle screws and interbodies with laminectomies

The study was performed at the LESS Institute by Professor Dr. Kingsley R Chin, MD, a board-certified orthopedic spine surgeon and coauthors Dr. Fabio Pencle and Dr. Jason Seale.

The study was a retrospective review of prospectively collected data under an IRB approved study cohort. The study evaluated 122 surgical cases of lumbar decompression with interspinous fixation from September 2011 to October 2016. A total of 56 patients had instrumentation at L4-L5. Total female population was 46%. The median age of the patients included in the population was 50.9+/-10.7 years with a median BMI of 24.8+/-11.4 kg/m2. Two-year VAS and ODI showed significant improvement form 8.1+/-1.2 to 1.5+/-1.1 and 42.9+/-14.3 to 14.8+/-5.1. All surgeries were completed in less than one hour. There was a total of one revision case with removal of Inspan and converted to an open hemilaminectomy decompression.

In conclusion, the long-term outcome of the study demonstrated improved outcomes in patients who underwent interspinous distraction decompression in an ambulatory surgery center using the Inspan device at L4-L5 for degenerative spinal stenosis. There were no complications or implant failures.

About INSPAN, LLC
INSPAN, LLC is privately owned by KICVentures and is focused on advancing the platform of patented interspinous fixation technology. The Inspan device has a proven ten-year track record with thousands implanted since FDA-clearance in 2010.

Inspan FDA Indications
The Inspan Slim Spinous Process Plate System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1). It is intended for plate fixation/attachment to the spinous process for the purpose of achieving supplemental fusion for the following indications: spondylolisthesis, trauma (fracture ordislocation), tumor, or degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies). The device is intended for use with bone graft material and is not intended for stand-alone use.

Read the full story at https://www.prweb.com/releases/5_year_follow_up_outpatient_of_l4_l5_fixation_with_inspan_device_for_degenerative_spinal_stenosis_demonstrates_improved_results/prweb16896859.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. AxioMed Announces 15-year Exclusive Worldwide License on Proprietary Viscoelastic Material with the patent holder DSM
2. Organogenesis Awarded a 5-Year Federal Supply Schedule Agreement with the Department of Veteran Affairs
3. Alexandria Real Estate Equities, Inc. Executes 15-Year Lease Extension with NIH for 60,000 RSF of Mission-Critical Space at Alexandrias 9800 Medical Center Drive Campus in Shady Grove Life Sciences Center
4. AxioMed Accomplishes Significant Milestone: Two-Year USA IDE Clinical Study Follow-Up Completed for Viscoelastic Lumbar Disc
5. Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
6. Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
9. Follow-up Tests Confirm Success of Enviro-Equipment Inc.’s Powdered Activated Carbon (PAC) CleanInject® Remediation System
10. AxioMed Energized by Publication Showing Success of Outpatient Cervical Disc Replacements
11. Newly Published Spine Surgery Study Shows Cervical Total Disc Replacement To Provide Better Results Than Fusion in Outpatient Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... ... January 27, 2020 , ... Cerebyte, ... cloud and mobile computing, today announced the availability of neuroscience of transformational leadership ... use the latest neuroscience of leadership and change research to become great transformational ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/10/2020)... , ... January 09, 2020 , ... ... Drug Development establishes benchmarks for the vendor qualification process, a critical element ... the process volume and complexity of the vendor qualification process creates delays in ...
(Date:1/7/2020)... ... January 07, 2020 , ... Absolute ... announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research ... from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions ...
Breaking Biology Technology:
(Date:2/5/2020)... ... February 05, 2020 , ... LabKey ... ease, efficiency and insight to sample processing within laboratories. , Built with ... conducting research in various fields, LabKey Sample Manager has been designed with an ...
(Date:1/29/2020)... THE WOODLANDS, Texas (PRWEB) , ... January 29, ... ... clinical grade DNA plasmid, announced it will start production of a DNA vaccine ... an agreement executed with Inovio Pharmaceuticals. A grant of up to $9 million ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... Shoreline ... to the strain level, today announced that the company will debut a novel new ... 26-29. , The new product, Shoreline Biome's Rapid Prep kit, is a fast ...
Breaking Biology News(10 mins):